PT3989961T - Uma combinação farmacêutica de um composto de artemisinina, ácido 5-aminolevulínico ou ácido metil-5-aminolevulínico e um agente quimioterapêutico - Google Patents

Uma combinação farmacêutica de um composto de artemisinina, ácido 5-aminolevulínico ou ácido metil-5-aminolevulínico e um agente quimioterapêutico

Info

Publication number
PT3989961T
PT3989961T PT217055417T PT21705541T PT3989961T PT 3989961 T PT3989961 T PT 3989961T PT 217055417 T PT217055417 T PT 217055417T PT 21705541 T PT21705541 T PT 21705541T PT 3989961 T PT3989961 T PT 3989961T
Authority
PT
Portugal
Prior art keywords
aminolevulinic acid
methyl
chemotherapeutic agent
pharmaceutical combination
artemisinin compound
Prior art date
Application number
PT217055417T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Jlp Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jlp Health Gmbh filed Critical Jlp Health Gmbh
Publication of PT3989961T publication Critical patent/PT3989961T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT217055417T 2020-02-19 2021-02-18 Uma combinação farmacêutica de um composto de artemisinina, ácido 5-aminolevulínico ou ácido metil-5-aminolevulínico e um agente quimioterapêutico PT3989961T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20158341.6A EP3868372A1 (en) 2020-02-19 2020-02-19 A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer

Publications (1)

Publication Number Publication Date
PT3989961T true PT3989961T (pt) 2024-02-26

Family

ID=69779738

Family Applications (1)

Application Number Title Priority Date Filing Date
PT217055417T PT3989961T (pt) 2020-02-19 2021-02-18 Uma combinação farmacêutica de um composto de artemisinina, ácido 5-aminolevulínico ou ácido metil-5-aminolevulínico e um agente quimioterapêutico

Country Status (15)

Country Link
US (1) US20230121771A1 (cg-RX-API-DMAC7.html)
EP (2) EP3868372A1 (cg-RX-API-DMAC7.html)
JP (1) JP7719787B2 (cg-RX-API-DMAC7.html)
KR (1) KR102988319B1 (cg-RX-API-DMAC7.html)
CN (1) CN114786661A (cg-RX-API-DMAC7.html)
AU (1) AU2021222339B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022014692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165208A1 (cg-RX-API-DMAC7.html)
DK (1) DK3989961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972799T3 (cg-RX-API-DMAC7.html)
FI (1) FI3989961T3 (cg-RX-API-DMAC7.html)
IL (1) IL294856A (cg-RX-API-DMAC7.html)
PL (1) PL3989961T3 (cg-RX-API-DMAC7.html)
PT (1) PT3989961T (cg-RX-API-DMAC7.html)
WO (1) WO2021165405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184234A1 (en) * 2020-11-30 2022-06-16 Sonalasense, Inc. Metabolic targeting of low grade tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2011225471A (ja) 2010-04-16 2011-11-10 Univ Of Tsukuba 抗癌剤の効果増強剤
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CN105963244A (zh) 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
CN106527586B (zh) * 2016-11-04 2019-09-06 吉林省北方医药有限责任公司 一种移动终端设备
CN108570089B (zh) * 2017-04-28 2019-10-29 云白药征武科技(上海)有限公司 双氢青蒿素-甾体结合物及其制备方法和应用
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
WO2021165405A1 (en) 2021-08-26
DK3989961T3 (da) 2024-01-29
JP2023514426A (ja) 2023-04-05
AU2021222339B2 (en) 2026-05-21
IL294856A (en) 2022-09-01
JP7719787B2 (ja) 2025-08-06
BR112022014692A2 (pt) 2022-09-20
KR102988319B1 (ko) 2026-07-07
CN114786661A (zh) 2022-07-22
EP3868372A1 (en) 2021-08-25
US20230121771A1 (en) 2023-04-20
EP3989961A1 (en) 2022-05-04
FI3989961T3 (fi) 2024-02-14
AU2021222339A1 (en) 2022-07-28
KR20220143097A (ko) 2022-10-24
PL3989961T3 (pl) 2024-04-08
CA3165208A1 (en) 2021-08-26
EP3989961B1 (en) 2023-11-22
ES2972799T3 (es) 2024-06-17

Similar Documents

Publication Publication Date Title
WO2011066980A3 (en) Oral dosage forms with reduced potential for drug abuse
EP4461358A3 (en) Salt of a pyrimido[6,1-a]isoquinolin-4-one compound
EP4101453A4 (en) COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
ZA202004058B (en) Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
GB202020191D0 (en) Pharmaceutical compounds
CA206651S (en) Pharmaceutical package
GB202010409D0 (en) Pharmaceutical compounds
MY201325A (en) Substituted nitrogen containing compounds
CA202028S (en) Pharmaceutical package
GB202010408D0 (en) Pharmaceutical compounds
PL3989961T3 (pl) Farmaceutycznе skojarzenie związku artemizyninowego, kwasu 5-aminolewulinowego lub kwasu metylo-5-aminolewulinowego i środka chemioterapeutycznego
SG11202112530VA (en) Pharmaceutical composition of a weak acid drug and methods of administration
CA232948S (en) Drug package
WO2011129579A3 (en) Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
GB202415076D0 (en) 5-pyridine-1h-indazole compound, pharmaceutical composition, and use
GB2593902B (en) Salt of a pharmaceutical compound
WO2010032165A3 (en) Prodrugs of artemisinin
GB202213819D0 (en) Pharmaceutical compound
IL319639A (en) Capsule inhaler for administration of a phosphodiesterase-4 inhibitor
EP4370109A4 (en) SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES AND NANOPARTICLES, AND METHODS OF USE THEREOF
GB202108612D0 (en) Ascorbic acid vial
CA203304S (en) Outer body for forming an anchor peg for tents
GB202102602D0 (en) Pharmaceutical compounds
GB202400072D0 (en) Drug detection
EP4365301A4 (en) Compound, manufacturing process therefor, antimicrobial agent and pharmaceutical